

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • AbbVie (adalimumab) • Pfizer (etanercept) • Janssen (ustekinumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Against Allergy • Action for Sick Children • Afiya Trust • Allergy UK • Black Health Agency • British Skin Foundation • Changing faces • Equalities National Council • Let's Face it • Muslim Council of Britain • National Children's Bureau • Psoriasis Association • Psoriasis and Psoriatic Arthritis Alliance • Psoriasis Help Organisation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association of Dermatologists • British Dermatological Nursing Group • British Geriatrics Society • British Skin Foundation • British Society for Cutaneous Allergy • British Society for Rheumatology • Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (methotrexate) • AMCo (methotrexate) • Dexcel Pharma (ciclosporin) • Hospira UK (infliximab, methotrexate) • Merck Sharp & Dohme (infliximab) • Napp Pharmaceuticals (infliximab) • Novartis (ciclosporin) • Orion Pharma (methotrexate) • Rosemont Pharmaceuticals (methotrexate) • Sandoz (methotrexate) • Santen UK (ciclosporin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Epidermo-Epidemiology Society • Centre of Evidence-based Dermatology, University of Nottingham

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Bradford Districts CCG • NHS Scarborough and Ryedale CCG • Welsh Government 	<ul style="list-style-type: none"> • Cochrane Skin Group • MRC Clinical Trials Unit • National Institute for Health Research • Skin Research Centre • Skin Treatment & Research Trust <p><u>Associated Guideline groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.